Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 18;57(3):2002695.
doi: 10.1183/13993003.02695-2020. Print 2021 Mar.

Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis

Affiliations

Phagosome-regulated mTOR signalling during sarcoidosis granuloma biogenesis

Elliott D Crouser et al. Eur Respir J. .

Abstract

Introduction: Sarcoidosis and tuberculosis are granulomatous pulmonary diseases characterised by heightened immune reactivity to Mycobacterium tuberculosis antigens. We hypothesised that an unsupervised analysis comparing the molecular characteristics of granulomas formed in response to M. tuberculosis antigens in patients with sarcoidosis or latent tuberculosis infection (LTBI) would provide novel insights into the pathogenesis of sarcoidosis.

Methods: A genomic analysis identified differentially expressed genes in granuloma-like cell aggregates formed by sarcoidosis (n=12) or LTBI patients (n=5) in an established in vitro human granuloma model wherein peripheral blood mononuclear cells were exposed to M. tuberculosis antigens (beads coated with purified protein derivative) and cultured for 7 days. Pathway analysis of differentially expressed genes identified canonical pathways, most notably antigen processing and presentation via phagolysosomes, as a prominent pathway in sarcoidosis granuloma formation. The phagolysosomal pathway promoted mechanistic target of rapamycin complex 1 (mTORc1)/STAT3 signal transduction. Thus, granuloma formation and related immune mediators were evaluated in the absence or presence of various pre-treatments known to prevent phagolysosome formation (chloroquine) or phagosome acidification (bafilomycin A1) or directly inhibit mTORc1 activation (rapamycin).

Results: In keeping with genomic analyses indicating enhanced phagolysosomal activation and predicted mTORc1 signalling, it was determined that sarcoidosis granuloma formation and related inflammatory mediator release was dependent upon phagolysosome assembly and acidification and mTORc1/S6/STAT3 signal transduction.

Conclusions: Sarcoidosis granulomas exhibit enhanced and sustained intracellular antigen processing and presentation capacities, and related phagolysosome assembly and acidification are required to support mTORc1 signalling to promote sarcoidosis granuloma formation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: L.W. Locke reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study. Conflict of interest: M.W. Julian reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study. Conflict of interest: S. Bicer reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study. Conflict of interest: W. Sadee reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study. Conflict of interest: P. White reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study. Conflict of interest: L.S. Schlesinger reports a grant from the Foundation for Sarcoidosis Research during the conduct of the study; grants from the National Institute of Health outside the submitted work. Conflict of interest: E.D. Crouser reports grants from the American Thoracic Society (ATS) Foundation/Mallinckrodt Pharmaceuticals, Inc. Research Fellowship in Sarcoidosis and the Foundation for Sarcoidosis Research during the conduct of the study.

Publication types

Substances

LinkOut - more resources